IVVD — Invivyd, Inc.

Invivyd, Inc. (IVVD) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Revenues: Q4 2025 net revenues from PEMGARDA increased by 31% compared to Q3 2025 and 25% year-over-year, totaling $53.4 million for the full year.
• Cash Position: The company ended 2025 with $226.7 million in cash and cash equivalents, providing a solid financial foundation to support ongoing operations and clinical trials.

2. Strategic Updates and Business Highlights

• Clinical Programs: The Revolution clinical program is progressing, focusing on VYD2311, a monoclonal antibody aimed at providing protection against symptomatic COVID-19. The Declaration study has reached its target enrollment of approximately 1,770 subjects.
• New Leadership: Invivyd appointed a new Chief Medical Officer, enhancing its leadership team.
• Commercial Growth: Continued expansion of PEMGARDA usage among healthcare providers (HCPs) and increased awareness of monoclonal antibodies as a treatment option. The company secured over 15,000 contracted GPO sites, indicating a robust commercial footprint.
• Pipeline Expansion: The company is exploring new indications for its antibodies, including long COVID and post-vaccine syndrome, and has identified a potentially best-in-class RSV antibody.

3. Forward Guidance and Outlook

• Clinical Trial Updates: The company expects to provide updates on the measles program in the first half of 2026. The Declaration study's results are anticipated by mid-2026, with potential for trial resizing based on event rates.
• Market Positioning: Invivyd aims to redefine COVID prevention with VYD2311 as a vaccine alternative, targeting broader populations.

4. Bad News, Challenges, or Points of Concern

• Regulatory and Market Risks: The company faces uncertainties related to the evolving COVID landscape and the potential need for trial resizing, which could impact timelines.
• Competitive Pressures: The antibody market, particularly for RSV, is competitive, with established products already in use. Invivyd's ability to differentiate its offerings will be crucial.
• Event Rate Dependency: The success of the Declaration study depends on community COVID attack rates, which are unpredictable and could affect the statistical power of the trial.

5. Notable Q&A Insights

• Trial Resizing: Management discussed the potential for resizing the Declaration study based on event rates, emphasizing a cautious approach to ensure adequate study power.
• Secondary Endpoints: While the primary focus remains on symptomatic COVID-19 prevention, the company will collect additional data on health care utilization and other secondary endpoints, though these may not significantly influence the study's power.
• Measles Antibody Use Cases: The anticipated measles antibody may serve multiple purposes, including outbreak prophylaxis and as a bridge therapy for vaccination, reflecting a broader strategy to enhance pediatric health outcomes.

Overall, Invivyd, Inc. is positioned for growth with a strong financial base and a promising clinical pipeline, but it must navigate competitive pressures and regulatory uncertainties as it advances its strategic initiatives.